|Traded as||LSE: VER NASDAQ: VNLS|
|Headquarters||Winnersh, United Kingdom|
Number of employees
Vernalis plc is a British based biotech company founded in 2003 by the merger of Vernalis Group with British Biotech in a deal valued at £90 million. The merger allowed British Biotech to ditch its historic but tarnished name.
The company has a development pipeline focused on CNS disease and oncology, and collaborates with pharmaceutical companies including Novartis, Servier, ChemGenex and Serono. It is listed on the London Stock Exchange and is a constituent of the FTSE Fledgling Index.
- "Vernalis agrees £91m merger plan with British Biotech". Advances in Life Science. ALS. 2003. Retrieved 3 July 2003.
- "Fifth Report". Select Committee on Science and Technology. House of Commons. 1998. Retrieved 28 November 2007.
- "Patient Information Sheet – Frovatriptan succinate (marketed as Frova)". Food and Drug Administration. July 2006. Archived from the original on 29 September 2007. Retrieved 28 November 2007.
- "Apokyn". FDA. 2004. Retrieved 29 July 2004.[dead link]
|This article about a medical, pharmaceutical or biotechnological corporation or company is a stub. You can help Wikipedia by expanding it.|